Indian Companies Make Cheaper Ozempic as Semaglutide Patent Ends March 2026

More than 1 billion people worldwide have a BMI of 30 or higher. Cheaper Ozempic versions are coming in March 2026, making treatment more accessible.
By Newsroom | Pharmaceuticals, India |

The impending expiry of the patent for semaglutide, the core component of the widely used weight-loss drugs Ozempic and Wegovy, is paving the way for Indian pharmaceutical firms to introduce more affordable generic versions. This shift is expected to dramatically increase global access to these treatments, which have seen immense demand for managing diabetes and obesity.

As the patent for semaglutide, the key ingredient in the popular weight-loss <b>drug</b> Ozempic, is ... - 1

Global Demand for Semaglutide Surges

Semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, has become a significant player in the pharmaceutical market. Initially approved for type 2 diabetes, its efficacy in promoting weight loss has led to widespread off-label use and a surge in demand.

As the patent for semaglutide, the key ingredient in the popular weight-loss <b>drug</b> Ozempic, is ... - 2

  • High Prevalence of Target Conditions: Globally, a substantial portion of the adult population lives with conditions for which semaglutide is prescribed. For example, in some regions, the proportion of adults living with obesity is as high as 36%, and those with diabetes is around 16%. The global population exceeds 8.23 billion, with over 1 billion people having a Body Mass Index (BMI) of 30 kg/m² or higher.

  • Drug's Dual Approval: Ozempic is approved for type 2 diabetes, while Wegovy is specifically approved for weight loss and management. Both utilize semaglutide, with dosage differences tailored to their intended use.

  • Market Impact: The drug's success has created an "unprecedented patent battle," with generic manufacturers aiming to capture a share of this lucrative market.

Patent Expiry and Generic Entry

The patent protection for semaglutide is a key factor determining when generic versions can enter the market.

As the patent for semaglutide, the key ingredient in the popular weight-loss <b>drug</b> Ozempic, is ... - 3

  • March 2026 Expiration: The patent for semaglutide is set to expire in March 2026 in several major countries. This date is crucial for the planned introduction of generic alternatives.

  • Complex Patent Landscape: Novo Nordisk secured patents in various regions, leading to differing expiration dates. This creates a complex environment for companies aiming to produce generics.

  • Regulatory Approvals: Companies are actively seeking regulatory approval for their generic versions. For instance, Dr. Reddy's Laboratories has already received approval from Indian regulators to manufacture and sell a generic version of Ozempic and is awaiting approval for a generic Wegovy.

Indian Pharmaceutical Companies Lead the Charge

Indian pharmaceutical companies are at the forefront of developing and producing generic semaglutide.

As the patent for semaglutide, the key ingredient in the popular weight-loss <b>drug</b> Ozempic, is ... - 4

  • Manufacturing Capacity: India has become an increasingly attractive location for pharmaceutical manufacturing. Indian giants are preparing to "flood the market" with generic versions once patents expire.

  • Legal Challenges: Some Indian companies, like Dr. Reddy's Laboratories and Natco Pharma, are engaged in legal battles with Novo Nordisk over patent validity. These court cases could determine how quickly cheaper versions become available in India.

  • Pricing Strategy: Generic manufacturers are anticipating significant price reductions. Dr. Reddy's has indicated that a 50-60% discount compared to the innovator drug is "very comfortable." The monthly cost of Wegovy in India currently ranges from approximately $119.65 to $16,400 Indian rupees for the lowest to highest doses, respectively.

  • Export Potential: There is potential for Indian generics to be exported, which could further expand global access. An interim court order in Delhi has allowed Dr. Reddy's and OneSource to continue manufacturing and exporting semaglutide.

Challenges and Future Outlook

While the entry of generics is anticipated, challenges remain.

Read More: New Wegovy Pill for Weight Loss Approved by FDA in Late 2025

  • Regulatory Hurdles: Evaluating generic semaglutide drugs is more complex than for many other medications, requiring thorough review by health authorities like Health Canada.

  • Limited Current Access: Despite its popularity, "most of the world still has only limited access to the drug," a situation expected to change dramatically with the advent of generics.

  • Novo Nordisk's Strategy: Novo Nordisk is likely preparing its strategy in anticipation of patent expiries and increased competition from generic manufacturers.

The expiration of semaglutide patents and the subsequent introduction of generic versions by companies like Dr. Reddy's Laboratories signal a significant shift in the weight-loss and diabetes drug market, with the potential to enhance accessibility and affordability for millions worldwide.

Sources

Frequently Asked Questions

Q: When will cheaper generic versions of Ozempic and Wegovy be available?
Cheaper generic versions of Ozempic and Wegovy, using the drug semaglutide, are expected to become available around March 2026. This is when the main patent for semaglutide expires in several countries.
Q: Which Indian companies are making generic Ozempic?
Indian companies like Dr. Reddy's Laboratories and Natco Pharma are preparing to launch generic versions of semaglutide. Dr. Reddy's has already received approval in India to make a generic Ozempic.
Q: How much cheaper will the generic versions be?
Generic versions are expected to be much cheaper. Dr. Reddy's has suggested they can offer discounts of 50-60% compared to the original drug. The current monthly cost in India can be around $119.65 for the lowest dose.
Q: Why is this important for people with diabetes and obesity?
These drugs, Ozempic and Wegovy, are very popular for treating type 2 diabetes and helping people lose weight. Many people around the world cannot afford them now. Cheaper generic versions will make these important treatments available to many more people.
Q: Are there any legal issues with these generic drugs?
Yes, some Indian companies are in court with Novo Nordisk, the maker of Ozempic, over the patents. These court cases could affect how soon the cheaper versions can be sold. However, some companies have interim court orders allowing them to make and export the drug.
Q: What does this mean for the global market?
The entry of affordable generic semaglutide will likely change the market a lot. It will increase access to these drugs globally, especially in countries where they are currently hard to get or too expensive.